Your browser doesn't support javascript.
loading
HIF1α Suppresses Tumor Cell Proliferation through Inhibition of Aspartate Biosynthesis.
Meléndez-Rodríguez, Florinda; Urrutia, Andrés A; Lorendeau, Doriane; Rinaldi, Gianmarco; Roche, Olga; Bögürcü-Seidel, Nuray; Ortega Muelas, Marta; Mesa-Ciller, Claudia; Turiel, Guillermo; Bouthelier, Antonio; Hernansanz-Agustín, Pablo; Elorza, Ainara; Escasany, Elia; Li, Qilong Oscar Yang; Torres-Capelli, Mar; Tello, Daniel; Fuertes, Esther; Fraga, Enrique; Martínez-Ruiz, Antonio; Pérez, Belen; Giménez-Bachs, Jose Miguel; Salinas-Sánchez, Antonio S; Acker, Till; Sánchez Prieto, Ricardo; Fendt, Sarah-Maria; De Bock, Katrien; Aragonés, Julián.
Afiliação
  • Meléndez-Rodríguez F; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain; CIBER de Enfermedades Cardiovasculares (CIBERCV), Carlos III Health Institute, Madrid, Spain.
  • Urrutia AA; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Lorendeau D; Laboratory of Cellular Metabolism and Metabolic Regulation, VIB Center for Cancer Biology, VIB, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000 Leuven, Belgium.
  • Rinaldi G; Laboratory of Cellular Metabolism and Metabolic Regulation, VIB Center for Cancer Biology, VIB, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000 Leuven, Belgium.
  • Roche O; Departamento de Ciencias Médicas, Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain; Laboratorio de Oncología, Unidad de Medicina Molecular, Centro Regional de Investigaciones Biomédicas/UCLM, Unidad Asociada de Biomedicina UCLM-CSIC, 02006 Albacete, Spain.
  • Bögürcü-Seidel N; Institute of Neuropathology, University of Giessen, Giessen, Germany.
  • Ortega Muelas M; Laboratorio de Oncología, Unidad de Medicina Molecular, Centro Regional de Investigaciones Biomédicas/UCLM, Unidad Asociada de Biomedicina UCLM-CSIC, 02006 Albacete, Spain.
  • Mesa-Ciller C; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Turiel G; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Bouthelier A; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Hernansanz-Agustín P; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Elorza A; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Escasany E; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Li QOY; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Torres-Capelli M; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Tello D; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Fuertes E; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Fraga E; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain.
  • Martínez-Ruiz A; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain; CIBER de Enfermedades Cardiovasculares (CIBERCV), Carlos III Health Institute, Madrid, Spain.
  • Pérez B; Centro de Diagnóstico de Enfermedades Moleculares, Centro de Biología Molecular-SO UAM-CSIC, Universidad Autónoma de Madrid, 28049 Madrid, Spain; CIBERER, Madrid, IdiPaz, Spain.
  • Giménez-Bachs JM; Servicio de Urología, Complejo Hospitalario Universitario de Albacete, Facultad de Medicina de la UCLM, Albacete, Spain.
  • Salinas-Sánchez AS; Servicio de Urología, Complejo Hospitalario Universitario de Albacete, Facultad de Medicina de la UCLM, Albacete, Spain.
  • Acker T; Institute of Neuropathology, University of Giessen, Giessen, Germany.
  • Sánchez Prieto R; Departamento de Biología del Cáncer, Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), Unidad Asociada de Biomedicina UCLM, Unidad Asociada al CSIC, Madrid, Spain; Departamento de Ciencias Médicas, Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.
  • Fendt SM; Laboratory of Cellular Metabolism and Metabolic Regulation, VIB Center for Cancer Biology, VIB, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000 Leuven, Belgium.
  • De Bock K; Department of Health Sciences and Technology, Swiss Federal Institute of Technology (ETH), Zurich, Switzerland.
  • Aragonés J; Research Unit, Hospital of Santa Cristina, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid 28009, Spain; CIBER de Enfermedades Cardiovasculares (CIBERCV), Carlos III Health Institute, Madrid, Spain. Electronic address: jaragones.hlpr@salud.madrid.org.
Cell Rep ; 26(9): 2257-2265.e4, 2019 02 26.
Article em En | MEDLINE | ID: mdl-30811976
ABSTRACT
Cellular aspartate drives cancer cell proliferation, but signaling pathways that rewire aspartate biosynthesis to control cell growth remain largely unknown. Hypoxia-inducible factor-1α (HIF1α) can suppress tumor cell proliferation. Here, we discovered that HIF1α acts as a direct repressor of aspartate biosynthesis involving the suppression of several key aspartate-producing proteins, including cytosolic glutamic-oxaloacetic transaminase-1 (GOT1) and mitochondrial GOT2. Accordingly, HIF1α suppresses aspartate production from both glutamine oxidation as well as the glutamine reductive pathway. Strikingly, the addition of aspartate to the culture medium is sufficient to relieve HIF1α-dependent repression of tumor cell proliferation. Furthermore, these key aspartate-producing players are specifically repressed in VHL-deficient human renal carcinomas, a paradigmatic tumor type in which HIF1α acts as a tumor suppressor, highlighting the in vivo relevance of these findings. In conclusion, we show that HIF1α inhibits cytosolic and mitochondrial aspartate biosynthesis and that this mechanism is the molecular basis for HIF1α tumor suppressor activity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Aspártico / Proteínas Supressoras de Tumor / Subunidade alfa do Fator 1 Induzível por Hipóxia / Neoplasias Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Aspártico / Proteínas Supressoras de Tumor / Subunidade alfa do Fator 1 Induzível por Hipóxia / Neoplasias Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha